Lung Cancer Canada is collecting data to support approval of crizotinib for ROS1+ non-small cell lung cancer in their country. Their deadline for submission is rapidly approaching, and they need more data to strengthen their case.
They would like ROS1+ patients who have taking crizotinib to share the following information (no names):
- Demographic data (e.g., age, gender, date of diagnosis)
- If currently or previously on crizotinib and for how long
- Responses to crizotinib (e.g., reduction in size of tumor, no response, cancer progression)
- Duration of the response
- Side effects (what type, have they resolved, if yes, how)
Please email your responses immediately to Iwo Effiong at iwo@LungCancerCanada.ca.
Thank you for helping more ROS1 patients obtain access to crizotinib!